ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Compounded Semaglutide Supervised Telehealth Weight Loss Program Announced

OrderlyMeds has announced a telehealth weight loss program that provides patients with compounded GLP-1/GIP, a more affordable alternative to branded medications.

-- Eligible individuals looking for cost-effective alternatives to Zepbound and other brands can enroll in OrderlyMeds’ recently announced weight loss program for prescription compounded semaglutide and tirzepatide. The program combines ongoing clinical support with holistic methods, including guidance on nutrition and physical activity, to promote long-lasting results for patients.

More information is available at https://orderlymeds.com/treatments/glp1s/compounded-glp1-gip/

Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are designed to mimic the GLP-1 hormone. This hormone is released into the gastrointestinal tract in response to food, which in turn stimulates the release of insulin from the pancreas; it also prolongs feelings of fullness and delays the emptying of the stomach. Because these effects reduce appetite, GLP-1 drugs are often prescribed in holistic weight loss programs in combination with other methods.

Common FDA-approved GLP-1 drugs include semaglutides such as Ozempic and Wegovy and tirzepatides such as Zepbound. However, because these medications are branded, they are often more expensive than generic options, especially when used in weight loss programs. To improve accessibility for patients, OrderlyMeds offers tailored compounded GLP-1 and GLP-1/GIP medications as more affordable alternatives to branded options; these are provided as part of its medically supervised telehealth weight loss programs.

Compounded medications are custom-made medications developed to fill a patient’s needs in the event of drug shortages or when indicated by a prescribing practitioner. For OrderlyMeds’ programs, patients are required to complete comprehensive online screening tests to determine eligibility for the medications and help the company’s licensed providers develop the best possible formula for long-term weight loss.

These custom GLP-1/GIP formulations offer a combination of semaglutide and tirzepatide, and they may include supportive additives, like vitamins B6 and B12, to improve digestive comfort, maintain muscle mass, and regulate energy levels.

The company offers two programs: a starter program, which includes 12 weekly doses that gradually increase in increments of 2.5 mg, and a transfer program for individuals who are already on GLP-1s. Regardless of the option, the medications will be delivered to the customer’s doorstep, allowing them to bypass wait times at the pharmacy.

In addition to ongoing medical support from OrderlyMeds’ providers, patients will also be advised on dietary changes, physical activity, mental healthcare, and other aspects of their overall health to promote sustained weight loss.

For more details, visit https://orderlymeds.com/

Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/

Source: PressCable

Release ID: 89181219

In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.77
-0.80 (-0.38%)
AAPL  255.92
+0.29 (0.11%)
AMD  217.50
+7.29 (3.47%)
BAC  49.38
+0.11 (0.22%)
GOOG  294.46
-0.44 (-0.15%)
META  574.46
-4.77 (-0.82%)
MSFT  373.46
+4.09 (1.11%)
NVDA  177.39
+1.64 (0.93%)
ORCL  146.38
+1.15 (0.79%)
TSLA  360.59
-20.67 (-5.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.